Smart & Biggar uncovers and maximizes intellectual property and technology assets for our clients.
Today’s fast-paced innovation economy demands a higher level of expertise and attention to detail when it comes to IP strategy and protection. With over 125 lawyers, patent agents and trademark agents collaborating across five Canadian offices, Smart & Biggar is trusted by the world’s leading innovators to find value in their IP rights.
As market leaders in IP, Smart & Biggar’s team is on the pulse when it comes to the latest developments and the wider industry changes that impact our clients. To stay informed, visit smartbiggar.ca/insights, including access to our RxIP Update (smartbiggar.ca/insights/rx-ip-updates), a monthly digest of the latest decisions and law surrounding the life sciences and pharmaceutical industries.
The Standing Committee on Health (HESA) of the House of Commons met on Thursday, April 27, 2023, to begin its study of the Patented Medicine Prices Review Board (PMPRB).
The Standing Committee on Health (HESA) of the House of Commons
met on Thursday, April 27, 2023, to begin its study of the Patented Medicine Prices Review
Board (PMPRB). The Committee first heard from the Minister of
Health, the Honourable Jean-Yves Duclos. The Minister's
appearance was followed by witnesses from the Department of Health
and the Department of Justice, as well as Mélanie Bourassa
Forcier, Professor at the University of Sherbrooke and the former
Acting Chair of the PMPRB.
The Committee will reconvene on May 2, 2023, to
hear from Matthew Herder, Associate Professor at Dalhousie
University and former board member of the PMPRB, as well as the
current Executive Director of the PMPRB, Douglas Clark.
The preceding is intended as a timely update on Canadian
intellectual property and technology law. The content is
informational only and does not constitute legal or professional
advice. To obtain such advice, please communicate with our offices
directly.
